{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2606.263","value":"6524.035"},{"groupId":"OG001","spread":"1415.318","value":"8855.687"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points. Pharmacokinetic (PK) analysis of Niraparib was conducted using standard non-compartmental analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Niraparib 200 milligrams (mg) orally once daily from Days 1 to 21 and Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 1: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants received Niraparib 300 mg orally once daily from Days 1 to 21 and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 1: Niraparib 300 mg + Pembrolizumab"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic Analysis Set comprised of all participants with sufficient data to enable estimation of at least one PK parameter. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)","title":"Phase 1: Area Under the Plasma Concentration-time Curve From Time 0 (Predose) to 24 Hours Post Dose (AUC [0-24]) of Niraparib","type":"SECONDARY","unitOfMeasure":"Hour*nanogram per milliliter"}